BK-5F-NM-AMT
| Clinical data | |
|---|---|
| Other names | βk-5F-NM-αMT; β-Keto-5-fluoro-N-methyl-αMT; β-Keto-5-fluoro-N-methyl-AMT; α,N-Dimethyl-5-fluoro-β-ketotryptamine; β-Oxo-5-fluoro-α-methyl-NMT |
| Drug class | Monoamine releasing agent |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C12H13FN2O |
| Molar mass | 220.247 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
BK-5F-NM-AMT, or βk-5F-NM-αMT, also known as β-keto-5-fluoro-N-methyl-αMT or α,N-dimethyl-5-fluoro-β-ketotryptamine, is a monoamine releasing agent of the tryptamine, α-alkyltryptamine, and β-ketotryptamine families.[1]
It is known to induce the release of serotonin and dopamine, with respective EC50 values of 190 nM and 620 nM in rat brain synaptosomes, whereas norepinephrine release was not reported.[1] In contrast to many other tryptamines, the drug is inactive as an agonist of serotonin receptors including the 5-HT1, 5-HT2, and 5-HT3 receptors.[1] In addition, unlike other α-alkyltryptamines like α-methyltryptamine (αMT), it is inactive as a monoamine oxidase inhibitor (MAOI).[1]
BK-5F-NM-AMT was first described in the literature by 2023.[1] It was patented by Matthew Baggott and Tactogen as a potential novel entactogen.[1] BK-5F-NM-AMT is the 5-fluoro derivative of BK-NM-AMT.[1][2][3][4] Other analogues of the drug include BK-5Cl-NM-AMT and BK-5Br-NM-AMT.[1]
See also
References
- ^ a b c d e f g h WO 2022061242, Baggott M, "Advantageous tryptamine compositions for mental disorders or enhancement", published 2023 March 24, assigned to Tactogen
- ^ Yadav BJ (16 July 2019). Understanding Structure–Activity Relationship of Synthetic Cathinones (Bath Salts) Utilizing Methylphenidate. Theses and Dissertations (Doctor of Philosophy thesis). Virginia Commonwealth University. p. 40. doi:10.25772/MJQW-8C64. Retrieved 24 November 2024 – via VCU Scholars Compass.
- ^ Blough BE, Decker AM, Landavazo A, Namjoshi OA, Partilla JS, Baumann MH, et al. (March 2019). "The dopamine, serotonin and norepinephrine releasing activities of a series of methcathinone analogs in male rat brain synaptosomes". Psychopharmacology (Berl). 236 (3): 915–924. doi:10.1007/s00213-018-5063-9. PMC 6475490. PMID 30341459.
- ^ US 20240335414, Baggott MJ , Dalziel S, "Specialized combinations for mental disorders or mental enhancement", published 10 October 2024, assigned to Tactogen Inc.
External links